Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Olaparib and Durvalumab (MEDI 4736) in Patients With IDH-Mutated Solid Tumors

NCT03991832 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT03991832
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03991832 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Olaparib and Durvalumab (MEDI 4736) in Patients With IDH-Mutated Solid Tumors
Lead sponsor
University Health Network, Toronto
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 31, 2019
Completion date
September 30, 2026
Enrollment
58 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma, glioma, idh mutation, solid tumor